Table 1.
Baseline patient characteristics
| Overall N = 572 |
Reduced BMI N = 191 |
Maintained BMI N = 191 |
Elevated BMI N = 190 |
p value | |
|---|---|---|---|---|---|
| Age, years | 71.0 (64.0, 77.0) | 72.5 (64.0, 79.0) | 70.0 (64.0, 77.0) | 71.0 (64.0, 75.5) | 0.36 |
| Sex, no. of men (%) | 442 (77.2%) | 152 (79.6%) | 148 (77.5%) | 142 (74.7%) | 0.53 |
| BMI (kg/m2) | 23.6 (21.9, 25.8) | 24.1 (22.0, 26.5) | 23.7 (22.0, 25.9) | 23.3 (21.4, 25.1) | 0.08 |
| High BMI, n (%) | 27 (4.7%) | 12 (6.3%) | 8 (4.2%) | 7 (3.7%) | 0.45 |
| Low BMI, n (%) | 27 (4.7%) | 6 (3.1%) | 9 (4.7%) | 12 (6.3%) | 0.34 |
| Hypertension, n (%) | 430 (75.2%) | 147 (77.0%) | 148 (77.5%) | 135 (71.1%) | 0.27 |
| Dyslipidemia, n (%) | 353 (61.7%) | 118 (61.8%) | 128 (67.0%) | 107 (56.3%) | 0.10 |
| Diabetes mellitus, n (%) | 205 (35.8%) | 73 (38.4%) | 74 (38.7%) | 58 (30.5%) | 0.17 |
| Smoking, n (%) | 322 (56.2%) | 110 (57.6%) | 108 (57.1%) | 104 (55.6%) | 0.92 |
| LDL cholesterol level (mg/dL) | 103.0 (84.0, 127.0) | 104.5 (87.0, 122.0) | 102.0 (81.0, 128.3) | 106.0 (83.0, 129.0) | 0.81 |
| HDL cholesterol level (mg/dL) | 47.0 (40.0, 56.0) | 45.0 (39.0, 56.0) | 47.0 (40.0, 55.0) | 47.0 (41.0, 57.0) | 0.46 |
| TG level (mg/dL) | 115.0 (82.5, 172.5) | 114.5 (74.0, 180.0) | 113.0 (83.8, 165.5) | 118.0 (85.5, 174.0) | 0.33 |
| HbA1c level (%) | 5.9 (5.6, 6.5) | 6.0 (5.6, 6.6) | 6.0 (5.6, 6.5) | 5.9 (5.5, 6.3) | 0.49 |
| eGFR, (mL/min/1.73 m2) | 65.2 (54.9, 78.8) | 65.5 (54.3, 74.4) | 67.3 (57.8, 81.3) | 62.5 (51.0, 79.5) | 0.20 |
| LVD, n (%) | 22 (11.7%) | 22 (11.7%) | 17 (9.0%) | 16 (8.8%) | 0.57 |
| EF (%) | 64.0 (55.0, 68.5) | 65.0 (56.0, 68.0) | 64.0 (54.9, 69.0) | 62.7 (53.0, 68.0) | 0.49 |
| Af, n (%) | 51 (8.9%) | 15 (7.9%) | 19 (9.9%) | 17 (8.9%) | 0.77 |
| Aspirin use, n (%) | 556 (97.2%) | 187 (98.4%) | 185 (97.9%) | 184 (97.9%) | 0.91 |
| Thienopiridines use, n (%) | 520 (90.9%) | 171 (90.0%) | 174 (92.1%) | 175 (93.1%) | 0.54 |
| Warfarin use, n (%) | 57 (10.0%) | 16 (8.4%) | 17 (9.0%) | 24 (12.8%) | 0.31 |
| Statins use, n (%) | 479 (83.7%) | 159 (83.7%) | 156 (83.0%) | 164 (87.2%) | 0.47 |
| ACEi use, n (%) | 201 (35.1%) | 67 (35.3%) | 66 (34.9%) | 68 (36.4%) | 0.95 |
| ARB use, n (%) | 209 (36.5%) | 66 (34.7%) | 73 (38.8%) | 70 (37.4%) | 0.70 |
| Β-blocker use, n (%) | 241 (42.1%) | 71 (37.4%) | 83 (44.4%) | 87 (46.5%) | 0.17 |
| No. of diseased vessels | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 0.80 |
| SYNTAX score | 11.0 (6.3, 18.3) | 12.0 (6.8, 18.0) | 11.0 (6.8, 19.1) | 10.5 (6.0, 19.0) | 0.85 |
| ACS, n (%) | 259 (45.3%) | 91 (47.6%) | 75 (39.3%) | 93 (48.9%) | 0.12 |
Data are shown as median and interquartile range otherwise or n (%)
ACE-I angiotensin-converting enzyme inhibitor, ACS acute coronary syndrome, Af atrial fibrillation, ARB angiotensin receptor blocker, BMI body mass index, EF ejection fraction, eGFR estimated glomerular filtration rate, HbA1C glycated hemoglobin, HDL high-density lipoprotein cholesterol, High BMI high body mass index (> 30 kg/m2), LDL-C low-density lipoprotein cholesterol, Low BMI low body mass index (< 18.5 kg/m2), LVD left ventricular dysfunction (ejection fraction < 40%), TG triglyceride, no. number